OmniAb (OABI) signied a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG, a joint venture between ArrowMark and Viking Global Investors. OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx. ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. Founded in 1999, Viking Global Investors is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages over $55B of capital across public and private investments.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OABI:
- OmniAb’s Earnings Call: Progress Amid Challenges
- OmniAb price target lowered to $7 from $10 at Craig-Hallum
- OmniAb Reports Q3 2025 Financial Results and Innovations
- OmniAb’s Innovative OmniUltra Technology and Strategic Operational Adjustments Drive Buy Rating
- OmniAb reports Q3 EPS (14c), consensus (14c)